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Background: Subclinical hypothyroidism (SCHo) is a common biochemical diagnosis in
older age. Evidence of impact is inconclusive and guidelines are inconsistent. With
increasing numbers of thyroid function tests (TFTs) performed, GPs frequently have to
makemanagement decisions regarding this diagnosis. However, little is known about how
SCHo is currently being managed in primary care.Aim: To explore management of SCHo
in primary care and GP reported rationale for treatment of SCHo in older individuals.
Design: Descriptive study using retrospective case note review and GP survey. Setting:
Nineteen General Practices, Central England, UK. Methods: Follow-up of a large cohort
with subsequent detailed review of individuals for whom therapy had been initiated fol-
lowing diagnosis of SCHo. Data on practice policies, and rationale behind treatment were
collected via GP questionnaire. Results: Forty-two individuals were treated following
identification of SCHo. Factors regarded as supporting instigation of therapy recorded by
practitioners included symptoms, a positive antithyroid antibody test and history of
radioiodine therapy. In all, 55% were registered at 3/19 practices suggesting significant
between practice variation. Reasons for testing included chronic disease check-up (n514),
presenting ‘thyroid symptoms’ (n55) and presenting other symptoms (n59). Reasons for
therapy initiation were only recorded in 26 cases and included presence of symptoms,
persistently high or increasing serum thyroid stimulating hormone concentration and
patient request. Only 2/15 GPs reported having practice guidelines on management.
Conclusion: Results suggest that GPs are uncertain how to interpret symptoms and TFT
results in older individuals. There is considerable variation in management of SCHo
between GPs with some GPs treating patients outside of all guideline recommendations.
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Background
Subclinical hypothyroidism (SCHo) is a biochem-
ical diagnosis characterised by a raised serum
thyrotrophin concentration (thyroid stimulating
hormone (TSH)) accompanied by a normal con-
centration of free thyroxine (FT4) and is found
frequently in older age (Wiersinga, 1995; Ross,
2001; Wilson et al., 2006). Recent estimates suggest
a UK prevalence of 2.6%–3.1% in individuals aged
65 years and above (Wilson et al., 2006). Diagnostic
rates are unknown and are likely to rise due to both
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an aging population and an increasing use of
thyroid function tests (TFTs) to rule out thyroid
dysfunction, with recent data showing that 10 mil-
lion TFTs are performed each year in the United
Kingdom with the majority of requests being
generated in primary care (Association for Clinical
Biochemistry, British Thyroid Association and
British Thyroid Foundation, 2006).
The clinical manifestation and consequences of
overt hypothyroidism are well established and can
be successfully treated through administration of
thyroxine replacement therapy. In contrast, there
is a lack of consensus with respect to the patho-
physiological consequences of SCHo particularly
in older individuals. Although SCHo is essentially
a biochemical diagnosis, some studies have repor-
ted a greater prevalence of symptoms in patients
with SCHo compared with age matched euthyroid
controls (Zulewski et al., 1997; Canaris et al., 2000;
Meier et al., 2001).
Others have suggested an association between
SCHo and raised serum lipids (Danese et al., 2000),
cardiac dysfunction (Biondi et al., 1999; Monzani
et al., 2001) and increased cardiac and all-cause
mortality (Rodondi et al., 2010). However, other
data show that raised TSH concentration confers a
survival benefit in octogenarians (Gussekloo et al.,
2004). The main argument advanced for treatment
of SCHo is the risk of progression to overt hypo-
thyroidism with progression rates varying from
2% to 17% (Gordin and Lamberg, 1981; Nystrom
et al., 1988; Parle et al., 1993; Vanderpump et al.,
1995). Risk of progression is further enhanced
in the presence of antithyroid antibodies and
with increasing serum thyrotrophin concentration
(Surks et al., 2004). With respect to treatment of
SCHo, trials have generally been small, with some
reporting an improvement in symptoms and others
failing to demonstrate any clinical benefits (Cooper
et al., 1984; Nystrom et al., 1988; Jaeschke et al.,
1996; Meier et al., 2001; Razvi et al., 2007; Parle
et al., 2010). In older individuals the benefits of
treatment must be balanced against the additional
risks associated with polypharmacy.
Overall, evidence relating to SCHo remains
inconclusive and deemed insufficient to justify
population screening or routine treatment. Recom-
mendations and guideline documents pertaining
to management of SCHo are inconsistent, being
based upon consensus opinion (see Table 1; Van-
derpump et al., 1996; Adlin, 1998; Surks et al., 2004;
Association for Clinical Biochemistry, British
Thyroid Association and British Thyroid Founda-
tion, 2006; Mayo Clinic, 2007; Villar et al., 2007;
NHS Clinical Knowledge Summaries, 2010). Few
data are available on how these recommendations
are taken up in routine care or how SCHo is
managed, and the aim of this study is therefore to
describe these.
Methods
In 2002–2003, the Birmingham Elderly Thyroid
Study (BETS) recruited 5881 individuals aged
65 years or more from 20 practices in central
England. A few patients were excluded on the
grounds of lack of capacity or serious illness, but
in all other respects the cohort represents a
community dwelling elderly population with 68%
of invited individuals participating. Full details of
the BETS cohort have been reported elsewhere
(Wilson et al., 2006).
Follow-up and re-screening of thyroid function
in this cohort (BETS2), excluding patients with
overt thyroid dysfunction, was undertaken in 19
of the original 20 practices after an interval
period of approximately five years. Overall, 3005
individuals from the baseline cohort participated
in follow-up (BETS2).
Thyroid function was defined by the TFT results
at re-screen or at initiation of thyroxine replace-
ment therapy where this had occurred in the
interval period between BETS1 and BETS2. TFTs
were extracted from GP records and tests may
have been performed in a variety of labora-
tories. Thyroid function was categorised as overt
hyperthyroid, subclinical hyperthyroid, euthyroid,
subclinical hypothyroid or overt hypothyroid in
accordance with standard reference criteria of the
main laboratory serving this GP area. Classification
was based purely on TFT result and did not include
consideration of symptoms. All BETS2 participants
who had commenced thyroxine replacement ther-
apy following a SCHo test result (defined by a
TSH concentration above reference range and FT4
within reference range), in the period between
screening for BETS1 and BETS2, were eligible for
inclusion in the current study.
Review of guideline documents and statements
of expert opinion informed development of the
case report form and defined data to be extracted
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Table 1 Summary of current guidelines
Guidelines/review Screening Diagnosis Treatment Factors to consider
British Thyroid Association
(Association for Clinical
Biochemistry, 2006)
Not in healthy population
Case finding can be appropriate:
women at menopause or with
non-specific symptoms
Raised TSH and normal
FT4, with repeat;
3–6/12 later
TSH.10, treatment is
recommended
TSH.10, monitor every three
years or annually if antibody
positive. A therapeutic trial of
thyroxine can be considered
Goitre, pregnancy
and rising TSH
ATA, AACE and Endocrine
Society Consensus
(Surks et al., 2004)
Recommends against population
screening
Aggressive case finding: high-risk
groups, symptomatic patients or
goitre
Raised TSH and
normal FT4
TSH.10, treatment is
reasonable
TSH.10, monitoring every
6–12 months
Antibody testing not
recommended as it does
not alter management
Pregnancy
NHS Clinical Knowledge
Summaries
(NHS Clinical Knowledge
Summaries, 2010)
Not in asymptomatic
patients
Case finding: goitre, sub-fertility,
hyperlipidaemia or diabetes.
Pregnant women
with a family history
Annually: radioiodine,
thyroid surgery, Lithium or
Amiodarone
Raised TSH and normal
FT4, with repeat 3-6/12
later.
TSH.10 treatment is
recommended
TSH.10, treatment not
recommended, a therapeutic
trial may be appropriate in
symptomatic patients
Goitre and rising
TSH
RCP Consensus Statement
(Vanderpump et al., 1996)
Unjustified in general population
Case finding: pregnant
women with type 1 DM,
radioiodine, thyroid surgery,
Lithium or Amiodarone
Raised TSH and normal
FT4 with no symptoms
Treatment recommended if
antibody positive
TSH.10, monitoring is
advised
American Association of
Family Practice
Patients .60 years
should be screened
Raised TSH and normal
FT4
TSH.10, treat if symptomatic
or antibody positive
(Adlin, 1998) TSH.10, monitor every six
months
Mayo Clinic
(Mayo Clinic, 2007)
ATA suggests screening
every five years for patients
over 35 years of age
ACP recommends screening
women over 50 years of age
Raised TSH and normal
FT4, after ruling out non-
thyroidal illness
TSH.10, expert opinion is to
treat
TSH.10, treatment based on
clinical judgement
Pregnancy, goitre,
young, mood
disorder, infertility,
antibodies, rising
TSH and hyperlipi-
daemia
Cochrane Review
(Villar et al., 2007)
Clinical judgement and patient
preference remain the best
manner to decide
ATA5American Thyroid Association; AACE 5American Association of Clinical Endocrinologists; RCP 5Royal College Physicians; DM
5Diabetes Mellitus; ACP 5American College of Physicians; NHS5National Health Service; TSH5 thyroid stimulating hormone; FT45 free
thyroxine.
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from the primary care records. The data collection
period was defined as the interval between baseline
thyroid function screening (BETS1) and com-
mencement of treatment. All consultations during
this interval period were reviewed and data extrac-
ted. Data extraction focused upon 12 symptoms
suggestive of overt hypothyroidism (muscle weak-
ness, muscle cramps, weight gain, cold intolerance,
constipation, lethargy, cognitive impairment, dry
skin, poor memory, hoarse voice, deep voice and
facial oedema) and nine other thyroid relevant
patient factors or clinical characteristics (goitre,
TSH concentration .10 mI/UL, depression, abnor-
mal lipid concentrations, advancing age, high cardi-
ovascular risk score, family history of hypo-
thyroidism, positive test for antithyroid antibodies
and patient requested TFT). TFT dates, results and
entire records of the consultation that triggered
requests for TFT and each subsequent discussion
related to initiation of replacement therapy were
extracted.
Consultations were classified as ‘thyroid relevant’
or not according to the reason for the consulta-
tion. Thyroid relevant consultations were further
categorised on the basis of two key decisions (i) to
perform a TFT or (ii) to commence thyroxine
replacement therapy. Patient demographics, includ-
ing age, gender and index of multiple deprivation
(IMD score 2004; a measure of deprivation; Noble
et al., 2010) were obtained from the original study
database.
In addition to case note review, one GP (the
research lead) in each of the participating
BETS practices was invited to complete a study
questionnaire. The GP questionnaire was devised
specifically to ascertain whether differences in
practice policies or routine procedures existed and
to identify which symptoms and/or other patient
characteristics were perceived to influence clinical
decision making with respect to management of
SCHo in older individuals. The questionnaire con-
sisted of 10 questions with categorical options and
a free text section for comments.
Statistical analysis
Data were entered into a Microsoft Access
database and analysed using the Statistical
Packages for Social Sciences (SPSS-17) Windows
package. All free text was reviewed and coded
to enable numerical content analysis. Data were
summarised using means with standard deviation
(SD) and corresponding range for data that
were normally distributed and median with inter-
quartile range (IQR) for data that were not nor-
mally distributed to describe current practice.
Results
Of the 3005 individuals followed up, 42 had com-
menced thyroxine replacement therapy following
an earlier test result indicating SCHo and were
therefore eligible for inclusion in the current study
(see Figure 1). These patients were registered at
14 of the 19 participating general practices with
three practices accounting for 55% of such cases.
Most (71.4%) were female and the mean age was
76.5 years (SD 5.49, range 66.8–88.3). Deprivation
scores (IMD 2004 score) ranged from 3.8 (least
deprived) to 60.8 (most deprived) with a median
score of 14.6 (IQR 22.16).
The mean interval period between baseline
thyroid function screening (BETS1) and initiation
of thyroxine replacement therapy was 2.52 years
(range 0.17–4.45 years), giving a total follow-up of
105.8 patient years. During the interval period
between baseline screening and commencement
of therapy, a total of 854 consultations were
recorded for these individuals; 17.4% (n5 149) of
these consultations were deemed to be ‘thyroid
relevant’, with a median number of 3.0 (IQR 3,
range 1–14) thyroid relevant consultations being
recorded per patient. Overall, 119 tests were
undertaken between baseline screen and initia-
tion of thyroxine therapy with 59 of these being
repeat tests after an initial subclinical result had
been received by the practice, equating to 1.4
confirmatory tests per patient before initiation of
treatment.
Requests for thyroid function testing
Indications for the index TFT (the test that first
indicated SCHo) were identified and recorded
(see Table 2). The BETS baseline screening TFT
was the index TFT for eight individuals and no
justification for conducting the index TFT was
recorded for 4/42 patients (Table 2).
Repeat TFTs were requested with a median
interval of 102 days (IQR 157.5, range 4–803)
following a result indicating euthyroid function
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and 96 days (IQR 136.5, range 4–412) after a
result indicating SCHo. Documented reasons for
repeating TFTs are presented in Table 2.
Initiation of thyroxine replacement therapy
Thyroxine replacement therapy was initiated in
32 (76%) patients following two TFTs confirming
SCHo. In 10 patients, replacement therapy was
initiated on the basis of a single TFT. TSH con-
centrations at the point of initiation of therapy are
presented in Figure 2. Median TSH was 7.1 mIU/L
(IQR 3.25, range 4.55–79.7) and median FT4 was
12.4 pmol/L (IQR 3.38, range 10.0–20.3). Reasons
for initiation of thyroxine therapy were only
documented for 26 of the 42 patients (61.9%) and
are presented in Table 2. Prior to initiation of
thyroxine replacement therapy measurement of
antithyroid antibody was undertaken for six
patients (five having a positive antibody titre).
GP questionnaire
Overall 15/19 (79%) GPs representing 15 prac-
tices, completed and returned the study ques-
tionnaire. Two (13%) GPs reported having practice
guidelines for management of SCHo. Most GPs
(67%; 10/15), however, reported discussing manage-
ment strategies with colleagues, with 6/15 (40%)
reporting having general discussion to clarify usual
practice and/or regarding specific patients.
Of the 12 symptoms suggestive of overt hypo-
thyroidism that could trigger a request for TFT or
influence the decision to initiate thyroxine, 91% of
GPs stated that presence of cold intolerance and
82% that cognitive dysfunction or weight gain
would trigger a TFT request (Table 3). Combina-
tions of symptoms increased likelihood of GPs
requesting a TFT and are presented in Table 3. One
GP reported that TFT was routinely conducted
in patients aged 65 years of age or more. When
asked about their prescribing practice, 12 (80%)
GPs reported ‘sometimes’ prescribing thyroxine
replacement therapy for SCHo. Three responded
that they had ‘never’ initiated treatment for SCHo,
however, three GPs (20%) reported being aware of
other GPs who routinely treated this borderline
state (see Table 3).
Twelve (92%) GPs reported that a serum TSH
concentration .10 mIU/L would influence their
decision to commence treatment for SCHo. The
932 Other
not eligible # 
42 Overt at
BETS
532
Deceased 
3005
Followed- up at
BETS2
2876 not
followed-up
5881 BETS 1 cohort
42 with Subclinical
hypothyroidism treated
with thyroxine prior to
the re-screen at BETS2
1245 No
response /
unwilling/ *
125 unable
to attend at
current time 
# Includes participants of BETS1 follow on trial who were subject to intervention outside of usual practice, patients with
unclassifiable thyroid function, patients excluded by their GP, 1 practice that did not participate in follow-up screening and
patients no longer registered with participating practices.
*Includes not available for follow-up (non-responding, non-contactable, unwilling to participate and non-consenting patients) 
Figure 1 Consort diagram defining study population. BETS5Birmingham Elderly Thyroid Study.
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presence of antithyroid antibodies (77%, n5 10),
raised serum lipid concentrations (62%, n5 8),
goitre (39%, n5 5), family history (39%, n5 5)
and depression (31%, n5 4) were also factors
reported to be likely to effect GP decision mak-
ing. Seven GPs reported that patient requests for
treatment were important considerations and two
suggested that decision making is influenced by
age .80 years and presence of cardiovascular
disease.
Discussion
Summary of the main findings
This study reviewed the routine primary care
records of 42 elderly patients prescribed thyrox-
ine replacement therapy in response to a TFT
result suggestive of SCHo to identify all thyroid
relevant consultations and examine indications
for TFT and initiation of treatment. Eight hun-
dred and fifty-four individual consultations were
reviewed to capture all relevant data. A survey
was also conducted to further explore GP ratio-
nale for diagnosing and managing SCHo in
patients aged 65 years or more.
The study showed considerable variation in
routine practice and between practices in the way
GPs manage elderly patients with SCHo, with five
practices not having initiated treatment on the
basis of a subclinical result for any patient within
the cohort and three practices accounting for 55%
(23/42) of treated cases. This study is unable to
comment on whether symptom burdens do differ
between practices and this may in part account
for the variation in practice. Importantly, GP
responses suggest that GPs are uncertain how to
manage SCHo in older individuals and that
management strategies are largely intuitive due
to a lack of clear evidence-based guidance to
support decision making, highlighting an impor-
tant training need.
In the current study, opportunistic thyroid func-
tion testing, undertaken during routine chronic
disease clinics or due to presence of no specific
symptoms lead to diagnosis of SCHo in more than
Table 2 Documented reasons for performing TFTs and initiation of thyroxine replacement therapy
Reasons for performing TFTs Index TFT (diagnosing
subclinical hypothyroidism;
n5 42 (%))
Reason for subsequent
TFTs (n559 (%))
Missing/no specific reason documented 4 (9.5) 4 (6.7)
Baseline screening TFT in BETS I 8 (19.0) N/A
Presence of symptoms suggestive of
hypothyroidism
5 (11.8) 4 (6.7)
Presence of non-specific symptoms 9 (21.4) 6 (10.2)
Routine chronic disease review clinic 14 (33.3) 9 (15.3)
Monitoring of prescribed iodine rich medication 1 (2.4) 3 (5.1)
Monitoring of subclinical hypothyroidism N/A 33 (56.0)
Family history 1 (2.4) N/A
Reasons for initiation of thyroxine replacement
therapy (documented for 26/42 patients)
TSH,10mIU/L
(19 patients; n (%))
TSH.10mIU/L
(7 patients; n (%))
Symptomatic (thyroid related symptoms) 12 (63.2) 4 (57.1)
Therapeutic trial 6 (31.6) –
FT4 ‘low normal’ 5 (26.3) –
TSH ‘rising’ 4 (21.1) –
Positive antithyroid antibody test 3 (15.8) –
Patient request 2 (10.5) 1 (14.3)
TSH ‘persistently raised’ 2 (10.5) 1 (14.3)
History of radioiodine therapy 1 (5.3) 1 (14.3)
On Amiodarone 1 (5.3) 1 (14.3)
Other 2 (10.5) 2 (28.6)
TFT5 thyroid function test; BETS5Birmingham Elderly Thyroid Study; TSH5 thyroid stimulating hormone;
FT45 free thyroxine.
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50% of cases. In only 12% of cases, the index TFT
diagnosing SCHo was triggered by the presence of
symptoms suggestive of hypothyroidism. Following
this biochemical diagnosis, GPs used a combination
of monitoring and treatment to manage SCHo.
TFTs were frequently and repeatedly requested
Figure 2 Serum thyrotrophin concentrations immediately prior to initiation of thyroxine replacement therapy.
TSH5 thyroid stimulating hormone.
Table 3 GP responses to questions relating to symptoms influencing management decisions
Proportion of GPs
reporting that in a
patient aged 65 years
or more they would
request a TFT based
upon presence of the
symptom in isolation,
% (n)
request a TFT based upon
presence of the symptom
accompanied by any other
symptom, % (n)
initiate T4 based
upon the presence
of the symptom
accompanied by any
other symptom, % (n)
Cognitive impairment 81.8 (9) 100 (14) 81.8 (9)
Poor memory 72.7 (8) 100 (14) 63.6 (7)
Weight gain 81.8 (9) 92.9 (13) 63.6 (7)
Lethargy 63.6 (7) 92.9 (13) 81.8 (9)
Cold intolerance 90.9 (10) 92.9 (13) 54.5 (6)
Constipation 45.5 (5) 85.7 (12) 45.5 (5)
Muscle weakness 54.5 (6) 78.6 (11) 36.4 (4)
Hoarse voice 54.5 (6) 78.6 (11) 45.5 (5)
Dry skin 45.5 (5) 78.6 (11) 54.5 (6)
Deep voice 36.4 (4) 71.4 (10) 36.4 (4)
Facial oedema 36.4 (4) 57.1 (8) 36.4 (4)
Muscle cramps 36.4 (4) 42.9 (6) 36.4 (4)
Any of the above if
impacting on quality
of life
N/A N/A 54.5 (6)
TFT5 thyroid function test.
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during the interval period between initial diagnosis
and initiation of treatment with an average of 1.4
additional TFTs being conducted per patient dur-
ing a mean interval period of 2.5 years. Repeated
tests were triggered by a variety of patient factors,
with monitoring of SCHo being the reason for
56% of the TFTs performed and presentation of
symptoms. In terms of frequency of TFTs, shorter
interval periods between TFTs were observed
following results indicating higher serum con-
centration of thyrotrophin compared with results
demonstrating borderline concentrations.
These findings are consistent with data reported
in other studies. Following examination of data
from a large healthcare database, Meyerovitch
et al. reported an average frequency of three GP
requested TFTs per person during a period of
five years with an increased rate of testing
with advancing age (Meyerovitch et al., 2007). In a
similar study, a range of between 0 and 5 requests
for TFTs were observed over a period of 12 months
in individuals with SCHo (Gibbons et al., 2010).
This is in line with the median repeat interval of
96 days after an initial subclinical result observed
in this study.
Few GPs in the current study reported using
practice guidelines for routine management of
SCHo. Most reported that their decision to initiate
thyroxine replacement therapy was made on a case-
by-case basis, driven predominantly by presence of
symptoms suggestive of overt hypothyroidism.
However, on the basis of the case review, only 12%
of patients had thyroid symptoms recorded prior to
the initial TFT. Unsurprisingly given the lack of
consistency in guideline and recommendation
papers, GP’s decision making in this study appears
to reflect a lower threshold for treating than
intended by guidelines, for example, in 81% of
cases GPs chose to initiate thyroxine therapy based
upon a serum thyrotrophin concentration below
10 mIU/L and treatment was frequently initiated
on the basis of a single subclinical result (24%).
Findings from focus group research in New Zealand
suggests that in the absence of guidelines or evi-
dence to direct testing and treatment, GPs man-
agement decisions were based on a host of factors,
including patient wishes, maintenance of a good
doctor–patient relationship and medicolegal
issues, and were not always based on symptom
presentations or other clinical factors (Gibbons
et al., 2009). Data from the current study
demonstrate that UK GPs adopt a similar non-
evidence-based approach to management of SCHo
in elderly individuals.
Limitations
The primary limitation of this study is the reli-
ance upon retrospective routine clinical data
recorded in the patient’s medical records (Mistry
et al., 2005). Full data capture for some patients
was not possible because the reasons for the test
request or initiation of treatment were not docu-
mented. Furthermore, data may be inaccurate
and/or incomplete due to documentation of only
those factors considered relevant to the investiga-
tion or treatment undertaken. Inclusion of the GP
questionnaire however enhanced data collection
and corroborated findings of the case note review.
This study did not aim to systematically identify
why GPs treat some patients with SCHo and not
others, but it is likely that recording in consulta-
tions where treatment is initiated differs from
recording in consultations where prescribing does
not occur. Bias introduced by such a retrospective
comparison is likely to have restricted the value
of a control group. Identification of all individuals
who had TFTs in the interval period could have
enabled further consideration of this issue. This
does not detract from the main findings of sig-
nificant practitioner variability, little adherence
to published recommendations in determining
treatment decisions and a clear call from GPs for
unified and consistent guidelines.
Routine practice with respect to TFT and
management of SCHo within these 19 practices
may be atypical as all participating practices had
previously taken part in a larger programme of
research exploring thyroid dysfunction in the
elderly and therefore had interest in the research
topic. The significant variation observed between
practices suggest this is unlikely to be the case, but
arguably interested practices are likely to be
demonstrating more informed practice and the
observed lack of adherence to recommendations is
likely to be even more evident elsewhere. Follow-
up of this cohort was not planned when the initial
2002–2003 study was undertaken. We therefore
feel that management of patients in the interval
period has been conducted in a largely naturalistic
setting and the variation between practices is a real
observation.
182 Jack Allport et al.
Primary Health Care Research & Development 2013; 14: 175–184
Conclusion
GPs are uncertain how to manage SCHo in older
individuals and strategies for management of
SCHo in the community therefore vary. Repeat
tests are conducted with varying frequency, which
is not informed by evidence, and thyroxine is pre-
scribed for varying reasons with limited scientific
rationale. These findings further demonstrate a
clear need for definitive evidence-based guidelines
to support GP decision making and to standardise
management of SCHo in the community.
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